{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:09:03Z","timestamp":1743134943218,"version":"3.40.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003483","name":"Hebrew University of Jerusalem","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>There is a potential link between cannabis and mental disorders\ufeff. Cannabis exposure involves in many cases negative mental emotions, which are unpleasant sensations or thoughts. Whereas mild cases of negative mental emotions inflict patient\u2019s quality of life, more severe cases lead to therapy discontinuations, or even hospitalizations and death. This study characterizes cannabis users who experienced negative mental emotions after cannabis exposure. The Releaf App database was utilized  to\u00a0evaluate the association between personal and cannabis use characteristics on reporting a negative mental emotion during cannabis exposure. This global mobile lets individuals track real-time cannabis experience use with cannabinoid-based products, containing data points such as gender, age, reason<jats:italic>s<\/jats:italic> for use, product type, cannabis composition, and feelings and emotions experienced after cannabis use. Multivariable logistic regression models were constructed, adjusting for potential confounders such as gender and previous experience with cannabis use. The study population comprised 4,435 users, and 34,279 sessions were collected from various countries, mainly from North America, and included in the primary analysis.\u00a0Reporting on negative mental emotions was associated with users in the age group of 18\u201330 years. Using cannabis for a mental purpose was associated with a small increase in reporting on negative mental emotions (OR\u2009=\u20091.10, 95%CI [1.03\u20131.19]). Oral products were associated with reporting on negative mental emotions. THC-dominant products were associated with reporting negative mental emotions compared to balanced products (OR\u2009=\u20091.21, 95%CI [1.06\u20131.38]). This study suggests that some characteristics of cannabis use, such as young age and oral consumption are associated with negative mental emotions. Further studies should examine the interface between cannabis consumption, characteristics of consumers, and negative emotional experience or even long-term mental disorders.<\/jats:p>","DOI":"10.1007\/s00406-024-01812-0","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T04:01:30Z","timestamp":1718078490000},"page":"407-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of Cannabis users and products and the experience of negative mental emotions following Cannabis use"],"prefix":"10.1007","volume":"275","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8525-5840","authenticated-orcid":false,"given":"Nir","family":"Treves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Yakirevich-Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiessam","family":"Abu Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Bonne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyad","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keenan","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branden","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Dautrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Matok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"1812_CR1","unstructured":"UNODC (2016) Annual prevalence of the use of drugs by region and globally, Statistics and Data. In: UNODC. https:\/\/dataunodc.un.org\/drugs\/prevalence_regional. Accessed 2 Jun 2019"},{"key":"1812_CR2","unstructured":"UNODC (2021) Prevalence-general | dataUNODC. In: United Nations. https:\/\/dataunodc.un.org\/data\/drugs\/Prevalence-general. Accessed 8 Apr 2021"},{"key":"1812_CR3","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/CPT.1381","volume":"105","author":"K Cohen","year":"2019","unstructured":"Cohen K, Weizman A, Weinstein A (2019) Positive and negative effects of cannabis and cannabinoids on health. Clin Pharmacol Ther 105:1139\u20131147. https:\/\/doi.org\/10.1002\/CPT.1381","journal-title":"Clin Pharmacol Ther"},{"key":"1812_CR4","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.2174\/13816128113199990620","volume":"20","author":"L Karila","year":"2014","unstructured":"Karila L, Roux P, Rolland B et al (2014) Acute and long-term effects of cannabis use: a review. Curr Pharm Des 20:4112\u20134118. https:\/\/doi.org\/10.2174\/13816128113199990620","journal-title":"Curr Pharm Des"},{"key":"1812_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/ADB.12968","author":"DJ Sholler","year":"2021","unstructured":"Sholler DJ, Strickland JC, Spindle TR et al (2021) Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addict Biolo. https:\/\/doi.org\/10.1111\/ADB.12968","journal-title":"Addict Biolo"},{"key":"1812_CR6","unstructured":"National Academies of Sciences E and M, Division H and M, Practice B on PH and PH, Agenda C on the HE of MAER and R (2017) The Health Effects of Cannabis and Cannabinoids. National Academies Press (US)"},{"key":"1812_CR7","doi-asserted-by":"publisher","first-page":"E131","DOI":"10.1161\/CIR.0000000000000883","volume":"142","author":"P Rl","year":"2020","unstructured":"Rl P, La A, Ra K et al (2020) Medical marijuana, recreational Cannabis, and cardiovascular health: a scientific statement from the american heart association. Circulation 142:E131\u2013E152. https:\/\/doi.org\/10.1161\/CIR.0000000000000883","journal-title":"Circulation"},{"key":"1812_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12889-021-11282-X","volume":"21","author":"MA Zenone","year":"2021","unstructured":"Zenone MA, Snyder J, Crooks V (2021) Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers. BMC Public Health 21:1\u201310. https:\/\/doi.org\/10.1186\/S12889-021-11282-X","journal-title":"BMC Public Health"},{"key":"1812_CR9","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/SCHBUL\/SBW003","volume":"42","author":"A Marconi","year":"2016","unstructured":"Marconi A, Di Forti M, Lewis CM et al (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 42:1262. https:\/\/doi.org\/10.1093\/SCHBUL\/SBW003","journal-title":"Schizophr Bull"},{"key":"1812_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","volume":"2","author":"M Di Forti","year":"2015","unstructured":"Di Forti M, Marconi A, Carra E et al (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2:233\u2013238. https:\/\/doi.org\/10.1016\/S2215-0366(14)00117-5","journal-title":"Lancet Psychiatry"},{"key":"1812_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(07)61162-3","volume":"370","author":"TH Moore","year":"2007","unstructured":"Moore TH, Zammit S, Lingford-Hughes A et al (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319\u2013328. https:\/\/doi.org\/10.1016\/S0140-6736(07)61162-3","journal-title":"Lancet"},{"key":"1812_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","volume":"6","author":"M Di Forti","year":"2019","unstructured":"Di Forti M, Quattrone D, Freeman TP et al (2019) The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 6:427\u2013436. https:\/\/doi.org\/10.1016\/S2215-0366(19)30048-3","journal-title":"Lancet Psychiatry"},{"key":"1812_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12967-020-02518-2\/TABLES\/5","volume":"18","author":"L Sharpe","year":"2020","unstructured":"Sharpe L, Sinclair J, Kramer A et al (2020) Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med 18:1\u201321. https:\/\/doi.org\/10.1186\/S12967-020-02518-2\/TABLES\/5","journal-title":"J Transl Med"},{"key":"1812_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.schres.2014.04.023","volume":"157","author":"WA van Gastel","year":"2014","unstructured":"van Gastel WA, Vreeker A, Schubart CD et al (2014) Change in cannabis use in the general population: a longitudinal study on the impact on psychotic experiences. Schizophr Res 157:266\u2013270. https:\/\/doi.org\/10.1016\/j.schres.2014.04.023","journal-title":"Schizophr Res"},{"key":"1812_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/eip.12693","volume":"12","author":"TCC Ragazzi","year":"2018","unstructured":"Ragazzi TCC, Shuhama R, Menezes PR, Del-Ben CM (2018) Cannabis use as a risk factor for psychotic-like experiences: A systematic review of non-clinical populations evaluated with the Community Assessment of Psychic Experiences. Early Interv Psychiatry 12:1013\u20131023. https:\/\/doi.org\/10.1111\/eip.12693","journal-title":"Early Interv Psychiatry"},{"key":"1812_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/acps.12108","volume":"129","author":"S Alemany","year":"2014","unstructured":"Alemany S, Arias B, Fatj\u00f3-Vilas M et al (2014) Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand 129:54\u201362. https:\/\/doi.org\/10.1111\/acps.12108","journal-title":"Acta Psychiatr Scand"},{"key":"1812_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1177\/0269881116660712","volume":"30","author":"A Bra\u00f1as","year":"2016","unstructured":"Bra\u00f1as A, Barrig\u00f3n ML, Garrido-Torres N et al (2016) U-shaped curve of psychosis according to cannabis use: New evidence from a snowball sample. J Psychopharmacol 30:1331\u20131338. https:\/\/doi.org\/10.1177\/0269881116660712","journal-title":"J Psychopharmacol"},{"key":"1812_CR18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/J.1360-0443.2005.01070.X","volume":"100","author":"RF Ferdinand","year":"2005","unstructured":"Ferdinand RF, Sondeijker F, Van Der Ende J et al (2005) Cannabis use predicts future psychotic symptoms, and vice versa. Addiction (Abingdon, England) 100:612\u2013618. https:\/\/doi.org\/10.1111\/J.1360-0443.2005.01070.X","journal-title":"Addiction (Abingdon, England)"},{"key":"1812_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94. https:\/\/doi.org\/10.1038\/tp.2012.15","journal-title":"Transl Psychiatry"},{"key":"1812_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYT.2021.630247\/FULL","volume":"12","author":"M Sorkhou","year":"2021","unstructured":"Sorkhou M, Bedder RH, George TP (2021) The behavioral sequelae of cannabis use in healthy people: a systematic review. Front Psychiatry 12:630247. https:\/\/doi.org\/10.3389\/FPSYT.2021.630247\/FULL","journal-title":"Front Psychiatry"},{"key":"1812_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/J.YEBEH.2017.08.039","volume":"76","author":"B Chen","year":"2017","unstructured":"Chen B, Choi H, Hirsch LJ et al (2017) Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 76:24\u201331. https:\/\/doi.org\/10.1016\/J.YEBEH.2017.08.039","journal-title":"Epilepsy Behav"},{"key":"1812_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-13-86\/TABLES\/4","volume":"13","author":"S Sockalingam","year":"2013","unstructured":"Sockalingam S, Tseng A, Giguere P, Wong D (2013) Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterol 13:1\u201310. https:\/\/doi.org\/10.1186\/1471-230X-13-86\/TABLES\/4","journal-title":"BMC Gastroenterol"},{"key":"1812_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/NEUROLINT13030038","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA et al (2021) Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int 13:387. https:\/\/doi.org\/10.3390\/NEUROLINT13030038","journal-title":"Neurol Int"},{"key":"1812_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1592\/PHCO.25.5.660.63590","volume":"25","author":"CD Mullins","year":"2005","unstructured":"Mullins CD, Shaya FT, Meng F et al (2005) Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 25:660\u2013667. https:\/\/doi.org\/10.1592\/PHCO.25.5.660.63590","journal-title":"Pharmacotherapy"},{"key":"1812_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYT.2022.880496\/BIBTEX","volume":"13","author":"K Li","year":"2022","unstructured":"Li K, Zhou G, Xiao Y et al (2022) Risk of suicidal behaviors and antidepressant exposure among children and adolescents: a meta-analysis of observational studies. Front Psychiatry 13:880496. https:\/\/doi.org\/10.3389\/FPSYT.2022.880496\/BIBTEX","journal-title":"Front Psychiatry"},{"key":"1812_CR26","doi-asserted-by":"crossref","unstructured":"McKinney W & Others (2010) Data structures for statistical computing in python. 51\u201356","DOI":"10.25080\/Majora-92bf1922-00a"},{"key":"1812_CR27","doi-asserted-by":"publisher","unstructured":"Kluyver T, Ragan-Kelley B, P\u00e9rez F, et al (2016) Jupyter Notebooks \u2013 a publishing format for reproducible computational workflows. Positioning and Power in Academic Publishing: Players, Agents and Agendas - Proceedings of the 20th International Conference on Electronic Publishing, ELPUB 2016 87\u201390. https:\/\/doi.org\/10.3233\/978-1-61499-649-1-87","DOI":"10.3233\/978-1-61499-649-1-87"},{"key":"1812_CR28","doi-asserted-by":"publisher","unstructured":"Brooks ME, Kristensen K, van Benthem KJ, et al (2017) glmmtmb balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. R Journal 9:378\u2013400. https:\/\/doi.org\/10.32614\/RJ-2017-066","DOI":"10.32614\/RJ-2017-066"},{"key":"1812_CR29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/PPE.12474","volume":"32","author":"G Bandoli","year":"2018","unstructured":"Bandoli G, Palmsten K, Chambers CD et al (2018) Revisiting the table 2 fallacy: a motivating example examining preeclampsia and preterm birth. Paediatr Perinat Epidemiol 32:390. https:\/\/doi.org\/10.1111\/PPE.12474","journal-title":"Paediatr Perinat Epidemiol"},{"key":"1812_CR30","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/AJE\/KWS412","volume":"177","author":"D Westreich","year":"2013","unstructured":"Westreich D, Greenland S (2013) The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol 177:292. https:\/\/doi.org\/10.1093\/AJE\/KWS412","journal-title":"Am J Epidemiol"},{"key":"1812_CR31","doi-asserted-by":"publisher","unstructured":"Bates D, M\u00e4chler M, Bolker BM, Walker SC (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67:1\u201348. https:\/\/doi.org\/10.18637\/JSS.V067.I01","DOI":"10.18637\/JSS.V067.I01"},{"key":"1812_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/J.2517-6161.1995.TB02031.X","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol) 57:289\u2013300. https:\/\/doi.org\/10.1111\/J.2517-6161.1995.TB02031.X","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"1812_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0121945","volume":"10","author":"B Diedenhofen","year":"2015","unstructured":"Diedenhofen B, Musch J (2015) cocor: a comprehensive solution for the statistical comparison of correlations. PLoS ONE 10:e0121945. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0121945","journal-title":"PLoS ONE"},{"key":"1812_CR34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0269881118760662","volume":"32","author":"MB Sami","year":"2018","unstructured":"Sami MB, Bhattacharyya S (2018) Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. J Psychopharmacol 32:825\u2013849","journal-title":"J Psychopharmacol"},{"key":"1812_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/19371918.2013.821351","volume":"29","author":"M Rubens","year":"2014","unstructured":"Rubens M (2014) Political and medical views on medical marijuana and its future. Soc Work Public Health 29:121\u2013131. https:\/\/doi.org\/10.1080\/19371918.2013.821351","journal-title":"Soc Work Public Health"},{"key":"1812_CR36","unstructured":"EMCDDA (2023) New psychoactive substances \u2013 the current situation in Europe (European Drug Report 2023). https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2023\/new-psychoactive-substances_en#level-3-section1"},{"key":"1812_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000517857","volume":"4","author":"AM Peterson","year":"2021","unstructured":"Peterson AM, Le C, Dautrich T (2021) Measuring the change in health-related quality of life in patients using marijuana for pain relief. Med Cannabis Cannabinoids 4:114\u2013120. https:\/\/doi.org\/10.1159\/000517857","journal-title":"Med Cannabis Cannabinoids"},{"key":"1812_CR38","unstructured":"Bedford E (2020) \u2022 Marijuana user status and consumption by gender Canada 2019 | Statista. In: Statista, Canada. https:\/\/www.statista.com\/statistics\/587715\/marijuana-consumption-canada-by-gender\/. Accessed 6 Jun 2022"},{"key":"1812_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/npp.2017.140","volume":"43","author":"ZD Cooper","year":"2017","unstructured":"Cooper ZD, Craft RM (2017) Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology 43:34\u201351. https:\/\/doi.org\/10.1038\/npp.2017.140","journal-title":"Neuropsychopharmacology"},{"key":"1812_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0272241","author":"AW Vickery","year":"2022","unstructured":"Vickery AW, Roth S, Ernenwein T et al (2022) A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years. PLoS One. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0272241","journal-title":"PLoS One"},{"key":"1812_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-021-02770-6","author":"N Treves","year":"2021","unstructured":"Treves N, Mor N, Allegaert K et al (2021) Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-021-02770-6","journal-title":"Sci Rep"},{"key":"1812_CR42","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/JAMAPSYCHIATRY.2020.1035","volume":"77","author":"LA Hines","year":"2020","unstructured":"Hines LA, Freeman TP, Gage SH et al (2020) Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiat 77:1044\u20131051. https:\/\/doi.org\/10.1001\/JAMAPSYCHIATRY.2020.1035","journal-title":"JAMA Psychiat"},{"key":"1812_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41380-021-01161-7","volume":"17","author":"M Solmi","year":"2021","unstructured":"Solmi M, Radua J, Olivola M et al (2021) (2021) Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry 17:1\u201315. https:\/\/doi.org\/10.1038\/s41380-021-01161-7","journal-title":"Mol Psychiatry"},{"key":"1812_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0925-4439(98)00042-8","volume":"1407","author":"F Berrendero","year":"1998","unstructured":"Berrendero F, Romero J, Garc\u00eda-Gil L et al (1998) Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Biochim Biophys Acta 1407:205\u2013214. https:\/\/doi.org\/10.1016\/S0925-4439(98)00042-8","journal-title":"Biochim Biophys Acta"},{"key":"1812_CR45","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1073\/PNAS.0336351100","volume":"100","author":"L Wang","year":"2003","unstructured":"Wang L, Liu J, Harvey-White J et al (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A 100:1393. https:\/\/doi.org\/10.1073\/PNAS.0336351100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1812_CR46","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5740\/JAOACINT.18-0208","volume":"102","author":"K Le","year":"2019","unstructured":"Le K (2019) A brief background on cannabis: from plant to medical indications. J AOAC Int 102:412\u2013420. https:\/\/doi.org\/10.5740\/JAOACINT.18-0208","journal-title":"J AOAC Int"},{"key":"1812_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/EJHPHARM-2020-002374","volume":"29","author":"N Fern\u00e1ndez-Bargiela","year":"2022","unstructured":"Fern\u00e1ndez-Bargiela N, Rotea-Salvo S, Margusino-Frami\u00f1\u00e1n L et al (2022) Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. Eur J Hosp Pharm 29:207\u2013211. https:\/\/doi.org\/10.1136\/EJHPHARM-2020-002374","journal-title":"Eur J Hosp Pharm"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01812-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-024-01812-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01812-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T20:12:40Z","timestamp":1743106360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-024-01812-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1007\/s00406-024-01812-0","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"type":"print","value":"0940-1334"},{"type":"electronic","value":"1433-8491"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest. Data was retrieved by the courtesy of MoreBetter, Ltd, creators of the Releaf App.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}